Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis

Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis — AI Research | MarketCI

VRTX

Market Closed

Vertex Pharmaceuticals Incorporated

NASDAQHealthcare Biotechnology

6.10K employees

CEO: Reshma Kewalramani

Founded: 1991

$451.63

+$0.00(+NaN%)

Market Cap

114.63B

Beta

0.31

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

VRTX Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for VRTX built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Buy

Pass %

71.43%

Score

5/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$410.80

AI Price Target

Machine learning • Price prediction

$454.62

Market Sentiment

News & social media analysis

0.11

Value Investor Price

Classic value analysis

$83.42

Financial Health

Bankruptcy risk assessment

11.57

Quality Score

Financial strength rating

5.00

AI Investment Grade

Deep analysis of filings & news

78.00

Key Investment Highlights

Important factors affecting VRTX investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

62.50% Good

Conditions Met

25.00/40.00

Due Diligence Score

62.50%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Pass
	Fail
	Pass
	Pass
	Pass

Showing 1 to 6 of 46 conditions